PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32717896-9 2020 Cytochrome P450 3A4 (CYP3A4) is the primary hepatic enzyme along with P-glycoprotein involved in the disposition of the vitamin D derivatives. Vitamin D 120-129 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 0-19 33920130-5 2021 The known factors affecting vitamin D metabolism interfere with cytochrome CYP3A4 activity. Vitamin D 28-37 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 75-81 33330279-14 2020 Conclusion: Exogenous factors (time of year, place of residence, and prophylactic administration of cholecalciferol), as well as endogenous factors (age and sex), play a determining role in the development of vitamin D deficiency and insufficiency; in contrast to genetic factors-polymorphic variants of the genes of xenobiotic phase 1 enzymes (CYP2C9, CYP2C19, CYP2D6, and CYP3A4) and the VDR gene-which do not play such role. Vitamin D 209-218 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 374-380 32681429-4 2020 It is known that several androgen-metabolizing P450s (CYP3A4/5/43 and CYP2B6) and P450 enzymes (CYP2R1, CYP27A1, CYP27B1, CYP24A1, CYP3A4, CYP2J2), which are necessary for vitamin D metabolism, are expressed in the prostate. Vitamin D 172-181 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 54-60 32867201-7 2020 Our results showed that the combination of the two compounds is able to counteract the appearance of an adipogenic phenotype, indicating a feedforward regulation on vitamin D metabolism by metformin, acting on CYP27B1 and CYP3A4. Vitamin D 165-174 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 222-228 32717896-9 2020 Cytochrome P450 3A4 (CYP3A4) is the primary hepatic enzyme along with P-glycoprotein involved in the disposition of the vitamin D derivatives. Vitamin D 120-129 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 21-27 30205156-11 2019 With the current extensive knowledge on the reactions and pathways of metabolism of vitamin D, especially those catalyzed by CYP24A1, CYP27A1, CYP27B1, CYP3A4 and CYP11A1, it is likely that many other of the resulting hydroxyvitamin D metabolites will be measured in human serum in the future, some contributing to a more detailed understanding of vitamin D status in health and disease. Vitamin D 225-234 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 152-158 30058048-0 2019 Drug-metabolizing enzymes CYP3A as a link between tacrolimus and vitamin D in renal transplant recipients: is it relevant in clinical practice? Vitamin D 65-74 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 26-31 30058048-1 2019 CYP3A enzymes are involved in the metabolism of calcineurin inhibitor tacrolimus as well as vitamin D. Vitamin D 92-101 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 0-5 30205156-11 2019 With the current extensive knowledge on the reactions and pathways of metabolism of vitamin D, especially those catalyzed by CYP24A1, CYP27A1, CYP27B1, CYP3A4 and CYP11A1, it is likely that many other of the resulting hydroxyvitamin D metabolites will be measured in human serum in the future, some contributing to a more detailed understanding of vitamin D status in health and disease. Vitamin D 84-93 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 152-158 30248338-4 2018 The mRNA levels of hepatic VDR- and vitamin D-related genes [cytochrome P450 (CYP) 2R1, CYP27A1, and CYP3A4] were higher in NAFL patients compared with normal liver subjects. Vitamin D 36-45 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 101-107 29461981-0 2018 CYP3A4 mutation causes vitamin D-dependent rickets type 3. Vitamin D 23-32 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 0-6 29153269-14 2018 CONCLUSIONS: Genetic mutants in vitamin D pathway (GC, CYP3A4, CYP24A1, and NADSYN1/DHCR7) had significant associations with 25(OH)D levels among pregnant women in southeast China. Vitamin D 32-41 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 55-61 29461981-4 2018 In vitro, the mutant CYP3A4 oxidized 1,25-dihydroxyvitamin D with 10-fold greater activity than WT CYP3A4 and 2-fold greater activity than CYP24A1, the principal inactivator of vitamin D metabolites. Vitamin D 51-60 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 21-27 29461981-4 2018 In vitro, the mutant CYP3A4 oxidized 1,25-dihydroxyvitamin D with 10-fold greater activity than WT CYP3A4 and 2-fold greater activity than CYP24A1, the principal inactivator of vitamin D metabolites. Vitamin D 51-60 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 99-105 29461981-5 2018 As CYP3A4 mutations have not previously been linked to rickets, these findings provide insight into vitamin D metabolism and demonstrate that accelerated inactivation of vitamin D metabolites represents a mechanism for vitamin D deficiency. Vitamin D 100-109 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 3-9 29461981-5 2018 As CYP3A4 mutations have not previously been linked to rickets, these findings provide insight into vitamin D metabolism and demonstrate that accelerated inactivation of vitamin D metabolites represents a mechanism for vitamin D deficiency. Vitamin D 170-179 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 3-9 29461981-5 2018 As CYP3A4 mutations have not previously been linked to rickets, these findings provide insight into vitamin D metabolism and demonstrate that accelerated inactivation of vitamin D metabolites represents a mechanism for vitamin D deficiency. Vitamin D 170-179 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 3-9 28418012-0 2017 CYP3A4 is a crosslink between vitamin D and calcineurin inhibitors in solid organ transplant recipients: implications for bone health. Vitamin D 30-39 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 0-6 28418012-5 2017 We also provide an overview of the literature on the interplay between vitamin D metabolism and CYP3A4 in experimental and clinical settings and discuss its possible implications for solid organ transplant recipients. Vitamin D 71-80 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 96-102 28418012-6 2017 In conclusion, there is a body of evidence on the interplay between vitamin D and the drug-metabolizing enzyme CYP3A4, which may have therapeutic implications. Vitamin D 68-77 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 111-117 28324001-0 2017 CYP3A4 Induction by Rifampin: An Alternative Pathway for Vitamin D Inactivation in Patients With CYP24A1 Mutations. Vitamin D 57-66 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 0-6 28817905-0 2017 Re: CYP3A4 Induction by Rifampin: An Alternative Pathway for Vitamin D Inactivation in Patients with CYP24A1 Mutations. Vitamin D 61-70 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 4-10 28324001-4 2017 CYP3A4 is a P450 enzyme that inactivates many drugs and xenobiotics and may represent an alternative pathway for inactivation of vitamin D metabolites. Vitamin D 129-138 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 0-6 28324001-10 2017 Conclusion: These observations suggest that rifampin-induced overexpression of CYP3A4 provides an alternative pathway for inactivation of vitamin D metabolites in patients who lack CYP24A1 function. Vitamin D 138-147 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 79-85 26970587-4 2016 CYP3A4 is the major drug-metabolising P450 in liver endoplasmic reticulum and can metabolise other active forms of vitamin D, so we examined its ability to metabolise 20(OH)D3. Vitamin D 115-124 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 0-6 26686945-3 2016 We therefore conducted a literature review to identify reports of statistically significant associations between single nucleotide polymorphisms (SNP) in 11 vitamin D pathway genes (DHCR7, CYP2R1, CYP3A4, CYP27A1, DBP, LRP2, CUB, CYP27B1, CYP24A1, VDR and RXRA) and non-bone health outcomes and circulating levels of 25-hydroxyvitamin D (25[OH]D and 1,25-dihydroxyvitamin D (1,25[OH]2D). Vitamin D 157-166 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 197-203 26827958-7 2016 Androgen inhibits vitamin D-mediated induction of CYP24A1, the calcitriol-degrading enzyme, while vitamin D promotes androgen inactivation by inducing phase I monooxygenases (e.g., CYP3A4) and phase II transferases (e.g., SULT2B1b, a DHEA-sulfotransferase). Vitamin D 98-107 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 181-187 26869438-5 2016 Specifically, CYP3A4 activity was increased up to 20-fold as compared to vitamin D treated wild-type Caco-2 cells. Vitamin D 73-82 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 14-20 26366751-4 2016 Vitamin D receptor activation using a vitamin D responsive element-mediated cytochrome P450 3A4 reporter gene assay was investigated in Caco-2 cells transfected with human vitamin D receptor. Vitamin D 38-47 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 76-95 23965431-0 2013 Effects of decreased vitamin D and accumulated uremic toxin on human CYP3A4 activity in patients with end-stage renal disease. Vitamin D 21-30 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 69-75 24655660-1 2014 In vitro studies have shown that vitamin D may induce several cytochrome P450 (CYP) enzymes in general and CYP3A4 in particular. Vitamin D 33-42 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 107-113 24486455-13 2014 In summary, our results suggest that ginsenosides, specifically aPPD and aPPT, inhibit the CYP3A4-mediated catabolism of active vitamin D3 in human liver and intestine, potentially providing additional vitamin D-related benefits to patients with cancer, neurodegenerative and metabolic diseases. Vitamin D 128-137 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 91-97 27022466-2 2015 In vitro studies have also shown that vitamin D may affect the expression of CYP3A4. Vitamin D 38-47 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 77-83 22985909-2 2013 This review focuses on two aspects: regulation of CYP3A4 expression by vitamin D and metabolism of vitamin D by CYP3A4. Vitamin D 71-80 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 50-56 22985909-2 2013 This review focuses on two aspects: regulation of CYP3A4 expression by vitamin D and metabolism of vitamin D by CYP3A4. Vitamin D 99-108 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 112-118 22985909-4 2013 The interplay between vitamin D and CYP3A4 provides new insights into our understanding of how enzyme induction can contribute to vitamin D deficiency. Vitamin D 130-139 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 36-42 23212742-2 2013 Human CYP24A1, CYP3A4, and CYP27B1 catalyze the inactivation and activation of vitamin D and have been implicated in the adverse drug response. Vitamin D 79-88 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 15-21 23307906-12 2013 Larger studies with stronger study designs are needed to clarify potential drug-vitamin D interactions, especially for drugs metabolized by cytochrome P450 3A4 (CYP3A4). Vitamin D 80-89 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 140-159 23307906-12 2013 Larger studies with stronger study designs are needed to clarify potential drug-vitamin D interactions, especially for drugs metabolized by cytochrome P450 3A4 (CYP3A4). Vitamin D 80-89 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 161-167 22205755-0 2012 An inducible cytochrome P450 3A4-dependent vitamin D catabolic pathway. Vitamin D 43-52 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 13-32 22903070-1 2012 Experimental studies on the molecular regulation of human drug metabolism have revealed that vitamin D up-regulates transcription of several key enzymes, such as CYP3A4, through the vitamin D receptor pathway in intestinal and hepatic cells. Vitamin D 93-102 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 162-168 22939842-2 2012 We report that exposure to the active hormonal form of vitamin D markedly increased gene expression of CYP3A4 and CYP3A5 and ultimately achieved levels of intracellular CYP3A enzyme activity within LNCaP prostate cancer cells that were comparable to that observed for Caco2 cells, an established model of CYP3A induction, and resulted in the increased turnover of testosterone to its inactive 6beta-OH metabolite. Vitamin D 55-64 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 114-119 22484315-8 2012 These data suggest VDR polymorphisms are predictors of intestinal CYP3A4, and that CYP3A4 intestinal expression varies seasonally--likely related to annual changes in UV sunlight and vitamin D levels. Vitamin D 183-192 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 83-89 22939842-2 2012 We report that exposure to the active hormonal form of vitamin D markedly increased gene expression of CYP3A4 and CYP3A5 and ultimately achieved levels of intracellular CYP3A enzyme activity within LNCaP prostate cancer cells that were comparable to that observed for Caco2 cells, an established model of CYP3A induction, and resulted in the increased turnover of testosterone to its inactive 6beta-OH metabolite. Vitamin D 55-64 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 103-109 22939842-2 2012 We report that exposure to the active hormonal form of vitamin D markedly increased gene expression of CYP3A4 and CYP3A5 and ultimately achieved levels of intracellular CYP3A enzyme activity within LNCaP prostate cancer cells that were comparable to that observed for Caco2 cells, an established model of CYP3A induction, and resulted in the increased turnover of testosterone to its inactive 6beta-OH metabolite. Vitamin D 55-64 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 103-108 22484315-1 2012 Vitamin D, whose levels vary seasonally with sunlight, is activated to 1alpha,25-dihydroxyvitamin D(3) that binds the vitamin D receptor (VDR) and transcriptionally regulates intestinal CYP3A4 expression. Vitamin D 0-9 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 186-192 22205755-3 2012 We now report a novel CYP3A4-dependent pathway, the 4-hydroxylation of 25-hydroxyvitamin D(3) (25OHD(3)), the induction of which may contribute to drug-induced vitamin D deficiency. Vitamin D 81-90 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 22-28 15578590-4 2005 We also show that LCA-VDR stimulates transcription of gene reporter constructs containing DR3 and ER6 vitamin D responsive elements (VDREs) from the human CYP3A4 gene. Vitamin D 102-111 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 155-161 20153625-4 2010 CM (10(-5) M) activated transcription of a luciferase plasmid containing the distal vitamin D responsive element (VDRE) from the human CYP3A4 gene at levels comparable to 1,25D (10(-8) M) in transfected human colon cancer cells (Caco-2). Vitamin D 84-93 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 135-141 16691293-8 2006 Combined with our previous findings that CYP3A4, not CYP24, plays the dominant role in hydroxylation of 1,25(OH)2D3 in human liver and intestine, our results indicate that SXR has a dual role in mediating vitamin D catabolism and drug-induced osteomalacia. Vitamin D 205-214 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 41-47 21349923-2 2011 Published in vitro data indicate that vitamin D may up-regulate the expression of the CYP3A4 gene. Vitamin D 38-47 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 86-92 21349923-4 2011 The aim of the present study was to investigate whether plasma concentrations of CYP3A4 drug substrates exhibit seasonal changes compatible with a stimulatory effect of vitamin D on drug metabolism. Vitamin D 169-178 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 81-87 19414624-8 2009 Higher protein expression of CYP3A4, MRP2, P-gp, and MRP4 was also observed after a 6-day treatment with other vitamin D analogs (100 nM 1alpha-hydroxyvitamin D(3),1alpha-hydroxyvitamin D(2) or Hectorol, and 25-hydroxyvitamin D(3)) in Caco-2 cells, suggesting a role of 1,25(OH)(2)D(3) and analogs in the activation of enzymes and transporters via the vitamin D receptor. Vitamin D 111-120 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 29-35 17965521-4 2007 The ability of CYP3A4 mRNA induction in LS180 cells was highly dependent on the site and number of vitamin D(3) and D(2) hydroxylation. Vitamin D 99-108 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 15-21 16344723-13 2006 Because CYP3A4 is involved in the vitamin D metabolism, rickets may have been the underlying selecting factor. Vitamin D 34-43 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 8-14 11723248-2 2001 We demonstrate the vitamin D analog, 19-nor-1alpha,25-dihydroxy vitamin D2, is also an effective inducer of CYP3A4 in Caco-2 cells, but with half the potency of 1,25-D3. Vitamin D 19-28 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 108-114 15546903-10 2005 Thus, CYP3A4 is both a 24- and 25-hydroxylase for vitamin D(2), 1 alpha OHD(2), and 1 alpha OHD(3). Vitamin D 50-59 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 6-12 11991950-1 2002 The fully active dihydroxylated metabolite of vitamin D(3) induces the expression of CYP3A4 and, to a lesser extent, CYP2B6 and CYP2C9 genes in normal differentiated primary human hepatocytes. Vitamin D 46-55 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 85-91 12016314-4 2002 Activation of VDR by LCA or vitamin D induced expression in vivo of CYP3A, a cytochrome P450 enzyme that detoxifies LCA in the liver and intestine. Vitamin D 28-37 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 68-73 15546903-4 2005 The ratio of rates of 24-hydroxylation of 1 alpha-hydroxyvitamin D(3) (1 alpha OHD(3)), 1 alpha OHD(2), and vitamin D(2) by CYP3A4 was 3.6/2.8/1.0. Vitamin D 57-66 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 124-130 12470639-4 2002 Six vitamin D responsive element (VDRE)-like sequences in the promoter region of the CYP3A4 gene were then individually tested for their ability to enhance transcription. Vitamin D 4-13 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 85-91 35569070-2 2022 Rifampin is an antituberculosis drug that is a potent inducer of cytochrome P450 3 subfamily A member 4 (CYP3A4), involved in an alternative catabolic pathway of vitamin D. Vitamin D 162-171 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 65-103 34719640-7 2021 We also summarize endogenous and exogenous substrates metabolized by CYP3A isoforms, such as cholesterol, bile acids, hormones, arachidonic acid, vitamin D, and drugs. Vitamin D 146-155 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 69-74 35380747-3 2022 However, there is growing evidence for a vitamin D-mediated increase of drug metabolism by induction of cytochrome P450 (CYP) 3A4. Vitamin D 41-50 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 104-129 35380747-7 2022 RESULTS: We observed a negative relationship between vitamin D and dose-adjusted antipsychotic drug concentrations, which was particularly pronounced for drugs which are predominantly metabolized via CYP3A4 (i.e., aripiprazole and quetiapine). Vitamin D 53-62 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 200-206 35380747-10 2022 CONCLUSION: Despite vitamin D"s potential benefits on physical and mental health, clinicians should be aware of its negative impact on blood concentrations of antipsychotics metabolized by CYP3A4 in patients with schizophrenia. Vitamin D 20-29 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 189-195 35569070-2 2022 Rifampin is an antituberculosis drug that is a potent inducer of cytochrome P450 3 subfamily A member 4 (CYP3A4), involved in an alternative catabolic pathway of vitamin D. Vitamin D 162-171 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 105-111 35625833-3 2022 As an inductor of cytochrome P450 3A4, a lack of vitamin D might aggravate cognitive deficits by increased exposure to anticholinergic antipsychotics. Vitamin D 49-58 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 18-37 35184385-5 2022 The results were confirmed in 3D spheroids, where 1alpha,25-dihydroxyvitamin D3 has comparable effect on CYP3A4 mRNA expression as 1alpha-hydroxyvitamin D3 , an active vitamin D metabolite. Vitamin D 168-177 cytochrome P450 family 3 subfamily A member 4 Homo sapiens 105-111